Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Diagnostics and laboratory products

SectorREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Diagnostics and laboratory products

Products and consumables used to analyse clinical specimens or physiological signals to detect, characterise or monitor disease. Includes in-vitro diagnostic reagents, analyser systems associated with those reagents, point-of-care testing kits, and diagnostic consumables; excludes general laboratory instruments and tools sold to life-science research organisations.

Market size
$92.4B
$92.4B ($86.5B–$119B) · 2025 · Triangulated
Growth
+4.8%
$147B by 2035
Attractiveness
75 /100
for B2B sellers
Evidence
Medium confidence
5 sources · Triangulated
Level
Sector
Segmented by
Product or service
Buyers
Hospitals, health systems, physician practices, ambulatory and alternative-care sites, public-health and reference laboratories
Value chain
Midstream
Maturity
Mature
Structure
Moderately concentrated
Buying triggers
  • New AI-enabled diagnostic device clearances [2]
  • Hospital and reference lab automation and lab-network consolidation tenders [10]
  • Alternative-site testing build-out by primary care and urgent-care operators [2]
  • Reimbursement or screening-programme expansion for molecular and oncology assays
Pains
  • Rising test volumes straining laboratory throughput and staffing capacity [1]
  • Fragmented instrument/reagent platforms raising total cost of ownership for labs
  • Pressure to cut cost per test while expanding menu breadth
  • Supply-chain fragility for single-use consumables and specialty reagents
Scores (1–5)
Pain intensity4
Purchasing power4
Reachability4
Growth3
Growth drivers
  • Aging populations and chronic disease prevalence raising test volumes [1]
  • Expansion of diagnostic laboratory networks and screening programmes [10]
  • Shift of testing into alternative care settings (urgent care, physician offices) [2]
  • AI-enabled diagnostics and record FDA authorisations opening new product cycles [2]
Headwinds
  • China healthcare pricing reform creating a multi-year structural headwind for cardiac and clinical chemistry portfolios in Asia-Pacific [7]
  • Instrument capital spending caution constraining new platform placements [7]
  • Post-COVID normalisation of testing revenue removing a large one-off volume base [7]
  • Reagent and consumable volume growth more moderate than pre-pandemic rates [7]
Trends
  • Kits leading product type mix [1]
  • Molecular panel adoption accelerating, especially in North America [1]
  • M&A deal value up 160% in H1 2026 vs H1 2025 [2]
  • Consolidation among the six largest listed diagnostics companies [3][4]

Submarkets 4

Split by customer type.

Submarket75/100

Clinical laboratories

Reagents, consumables and automated analysers supplied to hospital and reference laboratories for routine and specialised in-vitro testing.

$54.6B
Hospital and reference laboratories
Medium confidenceOpen
Submarket60/100

Point-of-care and ambulatory testing

Rapid diagnostic tests and compact analysers used in physician practices, urgent-care centres, emergency departments and alternative-care sites.

$18.5B
Physician practices, ambulatory and alternative-care sites
Low confidenceOpen
Submarket75/100

Molecular and specialised diagnostics

Molecular assays, sequencing-based products and specialty diagnostic systems for targeted disease, oncology and inherited-condition testing, including associated reagents and consu

$14.8B
Hospital laboratories, specialised diagnostic providers, biotechnology and pharmaceutical companies
Low confidenceOpen
Submarket50/100

Clinical consumables and general diagnostics

Single-use diagnostic consumables such as blood-collection, specimen-handling and swab products that support testing workflows but are not themselves assays.

$4.5B
Hospitals, laboratories, physician practices, ambulatory sites
Low confidenceOpen

How this was sized

$92.4B ($86.5B–$119B) · 2025 · Triangulated

Published estimates for clinical diagnostics span USD 86.5bn (2025, FMI [9]) to USD 118.6bn (2025, Phoenix [3][4]); Credence Research gives USD 92.37bn for 2025 rising to USD 147.31bn by 2035 at 4.78% CAGR [1]. Central point taken at USD 92.37bn (2025) with a range of 86.5-118.6bn reflecting definitional spread (kits vs kits+instruments+services). North America held 40.0% of global value in 2025 [1].

Alongside it in Healthtech & medtech

// Sell into Diagnostics and laboratory products

AOS finds the biggest accounts in this sector with a reason to talk now, maps their buying centre and prepares the outreach for your approval.